🚀 VC round data is live in beta, check it out!
Evommune Valuation Multiples
Discover revenue and EBITDA valuation multiples for Evommune and similar public comparables like Xeris Biopharma, TchaikaPharma, Gen İlaç, KalVista Pharmaceuticals and more.
Evommune Overview
About Evommune
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Founded
2020
HQ
Employees
45
Website
Sectors
Financials (LTM)
EV
$884M
Evommune Financials
Evommune reported last 12-month revenue of $12M and negative EBITDA of ($89M).
In the same LTM period, Evommune generated $12M in gross profit, ($89M) in EBITDA losses, and had net loss of ($78M).
Revenue (LTM)
Evommune P&L
In the most recent fiscal year, Evommune reported revenue of $13M and EBITDA of ($80M).
Evommune expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $12M | XXX | $13M | XXX | XXX | XXX |
| Gross Profit | $12M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($89M) | XXX | ($80M) | XXX | XXX | XXX |
| EBITDA Margin | (747%) | XXX | (613%) | XXX | XXX | XXX |
| EBIT Margin | (757%) | XXX | (624%) | XXX | XXX | XXX |
| Net Profit | ($78M) | XXX | ($69M) | XXX | XXX | XXX |
| Net Margin | (661%) | XXX | (530%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Evommune Stock Performance
Evommune has current market cap of $1B, and enterprise value of $884M.
Evommune's stock price is $28.65.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $884M | $1B | 5.6% | XXX | XXX | XXX | $-1.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEvommune Valuation Multiples
Evommune trades at 74.6x EV/Revenue multiple, and (10.0x) EV/EBITDA.
Evommune Financial Valuation Multiples
As of April 10, 2026, Evommune has market cap of $1B and EV of $884M.
Equity research analysts estimate Evommune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Evommune has a P/E ratio of (13.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $884M | XXX | $884M | XXX | XXX | XXX |
| EV/Revenue | 74.6x | XXX | 68.0x | XXX | XXX | XXX |
| EV/EBITDA | (10.0x) | XXX | (11.1x) | XXX | XXX | XXX |
| EV/EBIT | (9.9x) | XXX | (10.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 74.6x | XXX | — | XXX | XXX | XXX |
| P/E | (13.2x) | XXX | (15.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (11.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Evommune Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Evommune Margins & Growth Rates
Evommune's revenue in the last 12 month declined by (44%).
Evommune's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $2.1M for the same period.
Evommune's rule of 40 is (1302%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Evommune's rule of X is (1350%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Evommune Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (44%) | XXX | (32%) | XXX | XXX | XXX |
| EBITDA Margin | (747%) | XXX | (613%) | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | 40% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (1302%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (1350%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 213% | XXX | 154% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 663% | XXX | 570% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 724% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Evommune Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Xeris Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| TchaikaPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Gen İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| KalVista Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| uniQure | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Evommune M&A Activity
Evommune acquired XXX companies to date.
Last acquisition by Evommune was on XXXXXXXX, XXXXX. Evommune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Evommune
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEvommune Investment Activity
Evommune invested in XXX companies to date.
Evommune made its latest investment on XXXXXXXX, XXXXX. Evommune invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Evommune
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Evommune
| When was Evommune founded? | Evommune was founded in 2020. |
| Where is Evommune headquartered? | Evommune is headquartered in United States. |
| How many employees does Evommune have? | As of today, Evommune has over 45 employees. |
| Is Evommune publicly listed? | Yes, Evommune is a public company listed on NYSE. |
| What is the stock symbol of Evommune? | Evommune trades under EVMN ticker. |
| When did Evommune go public? | Evommune went public in 2025. |
| Who are competitors of Evommune? | Evommune main competitors are Xeris Biopharma, TchaikaPharma, Gen İlaç, KalVista Pharmaceuticals. |
| What is the current market cap of Evommune? | Evommune's current market cap is $1B. |
| What is the current revenue of Evommune? | Evommune's last 12 months revenue is $12M. |
| What is the current revenue growth of Evommune? | Evommune revenue growth (NTM/LTM) is (44%). |
| What is the current EV/Revenue multiple of Evommune? | Current revenue multiple of Evommune is 74.6x. |
| Is Evommune profitable? | No, Evommune is not profitable. |
| What is the current EBITDA of Evommune? | Evommune has negative EBITDA and is not profitable. |
| What is Evommune's EBITDA margin? | Evommune's last 12 months EBITDA margin is (747%). |
| What is the current EV/EBITDA multiple of Evommune? | Current EBITDA multiple of Evommune is (10.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.